C5aR Inhibitors
1 drugsAbout C5aR
C5aR, or complement component 5a receptor 1, is a protein crucial to the inflammatory arm of the innate immune system. As a receptor for C5a, its activation triggers chemotaxis, immune cell activation, and increased vascular permeability.
C5aR's involvement in inflammatory processes makes it a compelling drug target. Currently, there is no genetic evidence directly linking C5aR to specific diseases.
TAVNEOS is the only FDA-approved drug targeting C5aR, developed by CHEMOCENTRYX for inflammatory conditions. It is a small molecule approved in 2021.
Top C5aR Drugs
CHEMOCENTRYX is the only company with an approved drug targeting C5aR.
Low competition presents an opportunity, but also indicates potential challenges in the target space.
C5aR Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets C5aR, using small molecule modality.
Explore alternative modalities like antibodies to differentiate from existing therapies.
C5aR Clinical Trials 14 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on C5aR. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 5 | 4 | 0 | 1 | 100% |
| Phase 2 | 4 | 2 | 0 | 2 | 100% |
| Phase 3 | 3 | 1 | 0 | 2 | 100% |
| Phase 4 | 2 | 0 | 0 | 2 | - |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phase 3 Readout Calendar Pro
1 Phase 3 trial testing approved C5aR drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting C5aR. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
C5aR Drug Approval Timeline (2021 - 2021)
The first and only drug, TAVNEOS, was approved in 2021.
Recent approval suggests growing interest, but also early stage of market saturation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 5 (1 company)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on C5aR. A trial counts if an approved drug acting on C5aR is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.